Union Square Park Capital Management’s Starling Oncology, Inc. Warrant STLNW Stock Holding History

Union Square Park Capital Management’s Portfolio STLNW Stock Details STLNW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-120,000	Closed	-$66K	–	44
2022 Q3	$66K	Hold	120,000	–	–	0.06%	42
2022 Q2	$60K	Hold	120,000	–	–	0.06%	60
2022 Q1	$138K	Hold	120,000	–	–	0.05%	60
2021 Q4	$83K	Hold	120,000	–	–	0.03%	103
2021 Q3	$148K	Buy	+120,000	New	+$165K	0.05%	46

Other funds holding STLNW

LMR Partners London, United Kingdom $45.4B AUM 60.47% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

HCM

Highbridge Capital Management New York $3.09B AUM 31.21% 1-Year Est. Return

Walleye Capital New York $28B AUM 44.22% 1-Year Est. Return

DKCM

Davidson Kempner Capital Management New York $7.33B AUM 56.47% 1-Year Est. Return

CAC

Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return

DCM

Difesa Capital Management New York $38.1M AUM 39.86% 1-Year Est. Return

JFG

Jefferies Financial Group New York $14.6B AUM 40.95% 1-Year Est. Return

Man Group London, United Kingdom $55.1B AUM 24.23% 1-Year Est. Return

WAM

Wolverine Asset Management Chicago, Illinois $10.4B AUM 4.78% 1-Year Est. Return

Union Square Park Capital Management's STLNW Position: Q4 2022 in Review

Union Square Park Capital Management sold out of Starling Oncology, Inc. Warrant (STLNW) in Q4 2022, closing a stake of 120,000 shares — an estimated $66K sold.

Union Square Park Capital Management first reported a position in STLNW in Q3 2021 and held it in 5 quarters. The position peaked at $148K in Q3 2021. 13 funds tracked by Wall St. Rank hold STLNW as of Q4 2022.

Union Square Park Capital Management reported no remaining Starling Oncology, Inc. Warrant position as of Q4 2022 after selling out during the quarter.
Union Square Park Capital Management sold 120,000 Starling Oncology, Inc. Warrant shares in Q4 2022, an estimated $66K.
Union Square Park Capital Management first reported a position in Starling Oncology, Inc. Warrant in Q3 2021 and held it in 5 quarters.
Union Square Park Capital Management's Starling Oncology, Inc. Warrant position peaked at $148K in Q3 2021.
13 funds tracked by Wall St. Rank held Starling Oncology, Inc. Warrant as of Q4 2022.

Based on Union Square Park Capital Management's 13F filing for Q4 2022, filed 14 Feb 2023.